Latest News

  • Statement from Alkermes on Response to COVID-19 Read More
  • Journal of Clinical Psychiatry Publishes Data from Alkermes' Phase 3 ENLIGHTEN-1 Efficacy Study of ALKS 3831 in Patients With Schizophrenia Read More
  • Alkermes Response to Media Coverage of the Company and VIVITROL Read More

Investors

Working at Alkermes